Martina Fejtkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martina Fejtkova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Anna Sediva
2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital 2 Department of Immunology Prague
3 shared publications - Marketa Bloomfield
Department of Immunology, 2nd Faculty of Medicine, Motol and Homolka University Hospital, Charles University, Prague, Czech Republic
3 shared publications - Tomas Kalina
Childhood Leukaemia Investigation Prague (CLIP), Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol
3 shared publications Adam Klocperk
Department of Immunology, 2 Faculty of Medicine, Charles University and University Hospital Motol, Prague
2 shared publications- Irena Zentsova
Department of Immunology, 2nd Faculty of Medicine, Charles University, University Hospital in Motol, Prague, Czech Republic
2 shared publications - Zuzana Parackova
Department of Immunology, 2nd Faculty of Medicine Charles University, University Hospital in Motol, Prague, Czechia
2 shared publications
Latest Publications
- 3 January 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (3) , 338-351
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins
Our study presents a novel germline c.1715G>T (p.G572V) mutation in the gene encoding Toll‐like receptor 8 (TLR8) causing an autoimmune and autoinflammatory disorder in a family with monozygotic male twins, who suffer from severe autoimmune hemolytic anemia worsening with infections, and autoinflammation presenting as fevers, enteritis, arthritis, and CNS vasculitis. The pathogenicity of the mutation was confirmed by in vitro assays on transfected cell lines and primary cells. The p.G572V mutation causes impaired stability of the TLR8 protein, cross‐reactivity to TLR7 ligands and reduced ability of TLR8 to attenuate TLR7 signaling. This imbalance toward TLR7‐dependent signaling leads to increased pro‐inflammatory responses, such as nuclear factor‐κB (NF‐κB) activation and production of pro‐inflammatory cytokines IL‐1β, IL‐6, and TNFα. This unique TLR8 mutation with partial TLR8 protein loss and hyperinflammatory phenotype mediated by TLR7 ligands represents a novel inborn error of immunity with childhood‐onset and a good response to TLR7 inhibition.
- 3 January 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (3) , 338-351
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins
Our study presents a novel germline c.1715G>T (p.G572V) mutation in the gene encoding Toll‐like receptor 8 (TLR8) causing an autoimmune and autoinflammatory disorder in a family with monozygotic male twins, who suffer from severe autoimmune hemolytic anemia worsening with infections, and autoinflammation presenting as fevers, enteritis, arthritis, and CNS vasculitis. The pathogenicity of the mutation was confirmed by in vitro assays on transfected cell lines and primary cells. The p.G572V mutation causes impaired stability of the TLR8 protein, cross‐reactivity to TLR7 ligands and reduced ability of TLR8 to attenuate TLR7 signaling. This imbalance toward TLR7‐dependent signaling leads to increased pro‐inflammatory responses, such as nuclear factor‐κB (NF‐κB) activation and production of pro‐inflammatory cytokines IL‐1β, IL‐6, and TNFα. This unique TLR8 mutation with partial TLR8 protein loss and hyperinflammatory phenotype mediated by TLR7 ligands represents a novel inborn error of immunity with childhood‐onset and a good response to TLR7 inhibition.
- Open Access
- 18 October 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (1) , e32-e34
Lymphoproliferation, immunodeficiency and early-onset inflammatory bowel disease associated with a novel mutation in Caspase 8
Author contributions: VK and IZ designed, carried out and analyzed ex vivo experiments and immunophenotyping; HG, BR and TF designed, performed and analyzed genetic tests, KR performed structural analyses, AK contributed to clinical characterization of the patient and analyzed ex vivo experiments, MF performed ex vivo experiments and immunophenotyping, MB analyzed bone marrow aspirate and contributed to clinical characterization of the CASP8def patients, VK wrote the paper, TK, TF, and AS designed the project, supervised research, and wrote the paper.
- 18 October 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (1) , e32-e34
Open AccessLymphoproliferation, immunodeficiency and early-onset inflammatory bowel disease associated with a novel mutation in Caspase 8
Author contributions: VK and IZ designed, carried out and analyzed ex vivo experiments and immunophenotyping; HG, BR and TF designed, performed and analyzed genetic tests, KR performed structural analyses, AK contributed to clinical characterization of the patient and analyzed ex vivo experiments, MF performed ex vivo experiments and immunophenotyping, MB analyzed bone marrow aspirate and contributed to clinical characterization of the CASP8def patients, VK wrote the paper, TK, TF, and AS designed the project, supervised research, and wrote the paper.
- 22 June 2018
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 38 (5) , 589-601
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
Signal transducer and activator of transcription 1 gain-of-function (STAT1 GOF) mutations are the most common cause of chronic mucocutaneous candidiasis (CMC). We aim to report the effect of oral ruxolitinib, the Janus kinase (JAK) family tyrosine kinase inhibitor, on clinical and immune status of a 12-year-old boy with severe CMC due to a novel STAT1 GOF mutation.
- 22 June 2018
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 38 (5) , 589-601
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
Signal transducer and activator of transcription 1 gain-of-function (STAT1 GOF) mutations are the most common cause of chronic mucocutaneous candidiasis (CMC). We aim to report the effect of oral ruxolitinib, the Janus kinase (JAK) family tyrosine kinase inhibitor, on clinical and immune status of a 12-year-old boy with severe CMC due to a novel STAT1 GOF mutation.